文章：

促肿瘤宿主对癌症治疗的反应

The pro-tumorigenic host response to cancer therapies

原文发布日期：2019-10-23

DOI: 10.1038/s41568-019-0209-6

类型: Review Article

开放获取: 否

英文摘要：

Resistance to cancer therapy remains a major challenge in clinical oncology. Although the initial treatment phase is often successful, eventual resistance, characterized by tumour relapse or spread, is discouraging. The majority of studies devoted to investigating the basis of resistance have focused on tumour-related changes that contribute to therapy resistance and tumour aggressiveness. However, over the last decade, the diverse roles of various host cells in promoting therapy resistance have become more appreciated. A growing body of evidence demonstrates that cancer therapy can induce host-mediated local and systemic responses, many of which shift the delicate balance within the tumour microenvironment, ultimately facilitating or supporting tumour progression. In this Review, recent advances in understanding how the host response to different cancer therapies may promote therapy resistance are discussed, with a focus on therapy-induced immunological, angiogenic and metastatic effects. Also summarized is the potential of evaluating the host response to cancer therapy in an era of precision medicine in oncology.

摘要翻译： 

癌症治疗耐药性始终是临床肿瘤学领域的一项重大挑战。尽管初始治疗阶段常获成功，但以肿瘤复发或扩散为特征的最终耐药性仍令人沮丧。多数关于耐药机制的研究聚焦于导致治疗抵抗和肿瘤侵袭性的肿瘤相关变化。然而过去十年间，各种宿主细胞在促进治疗耐药中的多重作用日益受到重视。越来越多证据表明，癌症疗法可诱导宿主介导的局部和全身反应，这些反应往往会打破肿瘤微环境内的精妙平衡，最终促进或支持肿瘤进展。本综述探讨宿主对不同癌症疗法的反应如何导致治疗耐药的最新研究进展，重点关注治疗诱导的免疫学、血管生成和转移效应，并总结了精准医疗时代评估宿主对癌症治疗反应的潜在价值。

原文链接：

The pro-tumorigenic host response to cancer therapies